Your browser doesn't support javascript.
loading
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel, Sarah; Gassenmaier, Maximilian; Menzies, Alexander M; Loquai, Carmen; Johnson, Douglas B; Franklin, Cindy; Gutzmer, Ralf; Hassel, Jessica C; Weishaupt, Carsten; Eigentler, Thomas; Schilling, Bastian; Schummer, Patrick; Sirokay, Judith; Kiecker, Felix; Owen, Carina N; Fleischer, Maria I; Cann, Christopher; Kähler, Katharina C; Mohr, Peter; Bluhm, Leonie; Niebel, Dennis; Thoms, Kai-Martin; Goldinger, Simone M; Reinhardt, Lydia; Meier, Friedegund; Berking, Carola; Reinhard, Raphael; Susok, Laura; Ascierto, Paolo A; Drexler, Konstantin; Pföhler, Claudia; Tietze, Julia; Heinzerling, Lucie; Livingstone, Elisabeth; Ugurel, Selma; Long, Georgina V; Stang, Andreas; Schadendorf, Dirk; Zimmer, Lisa.
Afiliação
  • Knispel S; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Gassenmaier M; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Loquai C; Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
  • Johnson DB; Vanderbilt University Medical Center, Nashville, USA.
  • Franklin C; Department of Dermatology and Venereology, Skin Cancer Center at the Center of Integrated Oncology (CIO) Köln Bonn, University Hospital of Cologne, Cologne, Germany.
  • Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
  • Hassel JC; Skin Cancer Center, Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
  • Weishaupt C; Department of Dermatology, University Hospital of Muenster, Muenster, Germany.
  • Eigentler T; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
  • Schilling B; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.
  • Schummer P; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.
  • Sirokay J; Department of Dermatology, University Hospital Bonn, Bonn, Germany.
  • Kiecker F; Department of Dermatology, University Hospital Charité Berlin, Berlin, Germany.
  • Owen CN; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Fleischer MI; Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
  • Cann C; Vanderbilt University Medical Center, Nashville, USA.
  • Kähler KC; Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Mohr P; Department of Dermatology, Elbe-Klinikum Buxtehude, Buxtehude, Germany.
  • Bluhm L; Department of Dermatology, Elbe-Klinikum Buxtehude, Buxtehude, Germany.
  • Niebel D; Department of Dermatology, University Hospital Bonn, Bonn, Germany.
  • Thoms KM; Department of Dermatology, University Medical Center Goettingen, Göttingen, Germany.
  • Goldinger SM; Department of Dermatology, University Hospital Zürich, Zürich, Switzerland.
  • Reinhardt L; Department of Dermatology, Skin Cancer Center at the National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Meier F; Department of Dermatology, Skin Cancer Center at the National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Berking C; Department of Dermatology, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen - Metropolitan Region of Nuremberg, Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Reinhard R; Skin Cancer Unit, German Cancer Research Center (DKFZ) and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Mannheim, Germany.
  • Susok L; Department of Dermatology, St. Josef-Hospital Bochum, Bochum, Germany.
  • Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
  • Drexler K; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  • Pföhler C; Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany.
  • Tietze J; Department of Dermatology, University Hospital Rostock, Rostock, Germany.
  • Heinzerling L; Department of Dermatology, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen - Metropolitan Region of Nuremberg, Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Livingstone E; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Ugurel S; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Stang A; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Zimmer L; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Electronic address: lisa.zimmer@uk-essen.de.
Eur J Cancer ; 148: 61-75, 2021 05.
Article em En | MEDLINE | ID: mdl-33735811
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Morte Celular Programada 1 / Inibidores de Checkpoint Imunológico / Imunoterapia / Melanoma Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Morte Celular Programada 1 / Inibidores de Checkpoint Imunológico / Imunoterapia / Melanoma Idioma: En Ano de publicação: 2021 Tipo de documento: Article